Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Nov;30(5):737–742. doi: 10.1111/j.1365-2125.1990.tb03844.x

Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

J Sonne 1, S Boesgaard 1, H E Poulsen 1, S Loft 1, J M Hansen 1, M Døssing 1, F Andreasen 1
PMCID: PMC1368175  PMID: 2271373

Abstract

1. The effect of severe hypothyroidism on the pharmacokinetics and pharmacodynamics of oxazepam 15 mg given orally (n = 10) and the metabolism of paracetamol 750 mg given intravenously (n = 8) was investigated before and after treatment with levothyroxine. 2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01). 3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05). 4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid. 5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01). This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1. 6. Hypothyroidism was associated with decreased performance in a finger tapping test that was exacerbated by oxazepam. When the patients were euthyroid oxazepam did not produce any effect.

Full text

PDF
742

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown R. D., Manno J. E. ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1978 Dec;67(12):1687–1691. doi: 10.1002/jps.2600671214. [DOI] [PubMed] [Google Scholar]
  2. Eichelbaum M., Bodem G., Gugler R., Schneider-Deters D., Dengler H. J. Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med. 1974 May 9;290(19):1040–1042. doi: 10.1056/NEJM197405092901902. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M. Drug metabolism in thyroid disease. Clin Pharmacokinet. 1976;1(5):339–350. doi: 10.2165/00003088-197601050-00002. [DOI] [PubMed] [Google Scholar]
  4. Feely J., Stevenson I. H., Crooks J. Altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet. 1981 Jul-Aug;6(4):298–305. doi: 10.2165/00003088-198106040-00004. [DOI] [PubMed] [Google Scholar]
  5. Forfar J. C., Pottage A., Toft A. D., Irvine W. J., Clements J. A., Prescott L. F. Paracetamol pharmacokinetics in thyroid disease. Eur J Clin Pharmacol. 1980 Oct;18(3):269–273. doi: 10.1007/BF00563010. [DOI] [PubMed] [Google Scholar]
  6. Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980 Oct;215(1):86–91. [PubMed] [Google Scholar]
  7. Mølholm Hansen J., Skovsted L., Kampmann J. P., Lumholtz B. I., Siersbaek-Nielsen K. Unaltered metabolism of phenytoin in thyroid disorders. Acta Pharmacol Toxicol (Copenh) 1978 May;42(5):343–346. doi: 10.1111/j.1600-0773.1978.tb02214.x. [DOI] [PubMed] [Google Scholar]
  8. Poulsen H. E., Lerche A., Pedersen N. T. Phenobarbital induction does not potentiate hepatotoxicity but accelerates liver cell necrosis from acetaminophen overdose in the rat. Pharmacology. 1985;30(2):100–108. doi: 10.1159/000138057. [DOI] [PubMed] [Google Scholar]
  9. Scott A. K., Khir A. S., Bewsher P. D., Hawksworth G. M. Oxazepam pharmacokinetics in thyroid disease. Br J Clin Pharmacol. 1984 Jan;17(1):49–53. doi: 10.1111/j.1365-2125.1984.tb04998.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shenfield G. M. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet. 1981 Jul-Aug;6(4):275–297. doi: 10.2165/00003088-198106040-00003. [DOI] [PubMed] [Google Scholar]
  11. Sonne J., Loft S., Døssing M., Vollmer-Larsen A., Olesen K. L., Victor M., Andreasen F., Andreasen P. B. Bioavailability and pharmacokinetics of oxazepam. Eur J Clin Pharmacol. 1988;35(4):385–389. doi: 10.1007/BF00561369. [DOI] [PubMed] [Google Scholar]
  12. Sonne J., Poulsen H. E., Andreasen P. B. Single dose oxazepam has no effect on acetaminophen clearance or metabolism. Eur J Clin Pharmacol. 1986;30(1):127–129. doi: 10.1007/BF00614210. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES